Cell Culture Glycosylation Multi-scale Data Driven Mechanistic Modeling (Phase 2)

Develop software for next-generation N- and O-linked glycosylation mechanistic models for Adaptive Process Control of fed-batch Chinese Hamster Ovary (CHO) cell culture
Categories
Drug substance
Process control
Data
Project status
100% Completed

Industry Need

Glycosylation, one of the most common post-translational modifications (PTMs) for proteins, occurs via a complex set of reactions by which sugars are added to and removed from proteins. These glycans can impact folding stability, intracellular and extracellular targeting, and mediation of binding to host cells. In therapies, the glycoform distribution can impact the immunogenicity, circulatory half-life, pharmacokinetics, and effector functions. To ensure consistent product quality and glycoform distribution, an understanding of factors that affect the glycoforms is required. These factors range from protein structure around the glycosylation site to various genetic mutations, to host enzyme expression levels to culture conditions. Hybrid models which combine mechanistic information and equations with data-driven model elements can embody the information related to glycosylation to enable accurate prediction of glycosylation CQA based on current cell-culture process conditions and process variable set-points. Unanticipated causes of glycosylation variation, such as trace media component variability, can be addressed by inclusion of data-driven model elements which are trained frequently to adapt the models predictions with current information.

Solution

Use Glycosylation modeling to reduce laboratory experimentation. Calibrate predictive model using AI/ML rather than experiments.

Outputs/Deliverables

  • Modelling Software in Open-Source platform (2Q2024)
  • Model Use Training documentation (2Q2024)
  • Presentation – Model-based Design of Experiments for Glycosylation in CHO Cell Culture – 2023 AIChE Orlando, FL (Jing, Ma, Braatz (MIT))
  • Presentation – GlycoPy: A Multiscale Model-based Simulation, Optimization and Optimal Python Package for mAb Glycosylation in Cell Culture – 2023 AIChE Orlando, FL (Ma, Jing, Braatz (MIT))
  • Presentation – Model-based analysis of glycosylation across cell lines – 2023 BPI Boston, MA (Jing, Ma, Braatz (MIT))

Impacts

Reduce process development time and cost of Antibody products

Additional Project Information (Members Only)

Login to the NIIMBL member portal to access more, including: 

  • Updates
  • Value Proposition
  • Related Publications
  • Deliverables

Not yet a member? Learn more about which level of NIIMBL membership is right for you and your organization.

Project Lead

Massachusetts Institute of Technology

Massachusetts Institute of Technology

Participating Organizations

AstraZeneca

AstraZeneca

Boehringer Ingelheim

Boehringer Ingelheim

Bristol-Myers Squibb

Bristol-Myers Squibb

Cytiva

Cytiva

Federal Stakeholder:  National Institute of Standards and Technology

Federal Stakeholder: National Institute of Standards and Technology

Genentech, Inc.

Genentech, Inc.

Merck Sharp & Dohme LLC

Merck Sharp & Dohme LLC

MilliporeSigma/EMD Serono

MilliporeSigma/EMD Serono

NIIMBL

NIIMBL

Pfizer, Inc.

Pfizer, Inc.

Sanofi

Sanofi